

Intravenous (IV) Ibuprofen Market to Hit \$14.2 million & Registering at a 20.0% CAGR by 2022

Adults end user segment accounted for major share in 2021, and is projected to maintain this trend throughout the forecast period.

PORTLAND, OR, UNITED STATES, September 14, 2021 / EINPresswire.com/ -- UPDATE AVAILABLE ON-DEMAND [Intravenous (IV) Ibuprofen Market to Set New Growth Cycle]

According to the report by Allied Market Research, the global Intravenous (IV) Ibuprofen market is



expected to garner \$14.2 million by 2022, registering a CAGR of 20.0%. The research helps leading players and startups to devise new strategies based on current market trends and changing dynamics. Competitive landscape is mentioned in the report based on business segments, products portfolio, and strategic moves & developments of leading market players. Detailed segmentation assists in determining growing segments and determining further steps to capitalize on lucrative segments. Regional landscape is helpful in determining opportunities and driving factors of each region and taking further steps. The pain indication segment accounted for over three-fourths share in 2020 and is expected to maintain its dominance throughout the forecast period.

The major factors that boost the market growth include, increase in adoption of an intravenous mode of drug delivery for acute pain management due to faster onset of action as compared to the other routes (oral and transdermal mode of administration) and targeted drug delivery property.

Click Here To Access Free Sample Report @ <u>https://www.alliedmarketresearch.com/request-</u> <u>sample/1387</u>

COVID-19 scenario-

1) The Covid-19 pandemic and followed by lockdown has affected several manufacturing industries.

2) The prolonged lockdown resulted in a disrupted supply chain and increased the prices of raw materials.

3) However, as the world has been recovering from the pandemic, the market is estimated to get back on track.

The market growth is further augmented as IV ibuprofen improves pain management with less dependence on opioid analgesic medication, which may lead to several health complications such as sedation, dizziness, and others. Caldolor (Cumberland Pharmaceuticals) is the only injectable ibuprofen drug available in the market; hence, it has huge demand with minimal competition. However, numerous factors are likely to restrain the market growth such as lengthy approval process and limited geographic (country specific) approvals.

The U.S. is anticipated to remain the highest revenue-generating region during the forecast period, owing to the widespread adoption of IV Ibuprofen for treating pain and fever. However, Australia is expected to grow rapidly during the forecast period, owing to recent entry of IV Ibuprofen in this market, increasing awareness of non-steroidal anti-inflammatory drugs, and shifting trend towards intravenous mode of drug delivery.

The IV Ibuprofen market is dominated by Cumberland Pharmaceuticals and is actively engaged in research for the development of novel IV Ibuprofen products

Access Full Report @ https://www.alliedmarketresearch.com/Intravenous-Ibuprofen-market

The Major Key Players Are:

•Cumberland Pharmaceuticals Inc.
•Alveda Pharmaceuticals, Inc.
•(Acquired by Teligent, Inc.)
•CSL Limited
•Sandor Medicaids Pvt. Ltd.
•BT. Soho Industri Pharmasi
•Germin MED
•Grifols S.A.
•Elarbin Gloria Pharmaceuticals Co., Ltd.
•Al Nabeel International Ltd.
•Laboratorios Valmorca, C.A.

Key Findings of IV Ibuprofen Market:

•Bever is projected to be the fastest growing indication segment.

•Australia IV Ibuprofen market is expected to grow at the fastest CAGR of 14.7% from 2015 to 2020.

•In 2015, the U.S. and Canada collectively accounted for more than three-fourths of the global IV Ibuprofen market.

Trending Reports In Healthcare Industry:

Cochlear Implants Market Analysis & Industry Forecast, 2030

Diagnostic Catheters Market Analysis & Industry Forecast, 2030

Gastrointestinal Cancer Drugs Market Analysis & Industry Forecast, 2030

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa Allied Analytics LLP +1 -503-894-6022 email us here Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/551352286

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 IPD Group, Inc. All Right Reserved.